Pending COVID-19 testing was good news for investors in a Canadian biotech stock Tuesday. Here’s some small stocks making big moves on Tuesday, March 31, 2020 (as of 4 pm EST):
StageZero Life Sciences, Ltd. (TSX:SZLS), a Canadian biotech stock, powered 86% higher to $0.065 on Tuesday after announcing that it is preparing to offer testing for COVID-19 in both the U.S. and Canada. The Company added that it will offer both the serology point-of-care and lab-based PCR tests.
As well, shares of Park Lawn Corporation (TSX:PLC) slipped 17% to $16.50 as the deathcare services provider said its Q4 Adjusted Net Earnings per share on a fully-diluted basis fell 23.8% to $0.16. The Company added that it has increased overhead expenses in both its Toronto and Houston support offices as it integrates its acquisitions during 2019, which has had a “short term drag on earnings.”
The Flowr Corporation (TSXV:FLWR), meanwhile, reported that its wholly-owned subsidiary in Europe has received its Good Manufacturing Practice (GMP) certification in accordance with European Union standards, for its manufacturing facility in Sintra, Portugal. The Flowr Corp. stock moved up 21% to $0.76 following the announcement.
Finally, Tinkerine Studios Ltd. (TSXV:TTD) shares rose 14% to $0.16 after the provider of 3D printing products announced the receipt of additional orders of Tinkerine’s Face Shield Version 9 and has now received inquiries for more than 35,000 Face Shields.
Disclosure: Neither the author nor his family own shares in any of the companies mentioned above.
To read our full disclosure, please click on the button below:
The Content contained on this page (including any facts, views, opinions, recommendations, description of, or references to, products or securities) made available by SmallCapPower/Ubika Research is for information purposes only and is not tailored to the needs or circumstances of any particular person. Any mention of a particular security is merely a general discussion of the merits and risks associated there with and is not to be used or construed as an offer to sell, a solicitation of an offer to buy, or an endorsement, recommendation, or sponsorship of any entity or security by SmallCapPower/Ubika Research. The Reader should apply his/her own judgment in making any use of any Content, including, without limitation, the use of any information contained therein as the basis for any conclusions. The Reader bears responsibility for his/her own investment research and decisions. Before making any investment decision, it is strongly recommended that you seek outside advice from a qualified investment advisor. SmallCapPower/Ubika Research does not provide or guarantee any financial, legal, tax, or accounting advice or advice regarding the suitability, profitability, or potential value of any particular investment, security, or information source. Ubika and/or its affiliates and/or their respective officers, directors or employees may from time to time acquire, hold or sell securities and/or commodities and/or commodity futures contracts in certain underlying companies mentioned in this site and which may also be clients of Ubika’s affiliates. In such instances, Ubika and/or its affiliates and/or their respective officers, directors or employees will use all reasonable efforts to avoid engaging in activities that would lead to conflicts of interest and Ubika and/or its affiliates will use all reasonable efforts to comply with conflicts of interest disclosures and regulations to minimize the conflict.
StageZero Life Sciences, Ltd. (TSX:SZLS), a Canadian biotech stock, powered 86% higher to $0.065 on Tuesday after announcing that it is preparing to offer testing for COVID-19 in both the U.S. and Canada. The Company added that it will offer both the serology point-of-care and lab-based PCR tests.
, on Tuesday.){kind=link}